Non-viral delivery and optimized optogenetic stimulation of retinal ganglion cells led to behavioral restoration of vision by Ling Gu et al.
Nature Precedings  Article  
 
1Biophysics and Physiology Lab, Department of Physics, University of Texas-Arlington, TX 76019; 
2Department of Biomedical Engineering, 3Department of Ophthalmology, University of California-Irvine, CA 92617. 
*Corresponding author: Dr. Samarendra Mohanty, Department of Physics, University of Texas at Arlington,  502 Yates Street, 108 
Science Hall, Arlington, TX 76019, USA. Email smohanty@uta.edu,  
Tel. 817-272-1177. Fax: +1-817-272-3637. 
Non-viral delivery and optimized optogenetic stimulation of retinal ganglion cells led to 
behavioral restoration of vision 
 
 













Key words:  Retinitis Pigmentosa, Optogenetics, Electroporation, Retinal prosthesis, Optical imaging. 
 
 
Vision has a significant impact on physical, emotional as 
well as the psychological state of human health. 
Degeneration of photoreceptors in the eye in diseases 
such as retinitis pigmentosa (RP) gradually hinders visual 
ability of one million individuals worldwide1. More 
frequently (~15 million worldwide), people have severe 
loss of vision due to other diseases such as age-related 
macular degeneration (AMD) when degeneration of 
photoreceptors of the eye hinders the visual cortex from 
receiving signals from retinal ganglion cells, thus 
preventing image information1-4. To date, there is no 
reliable method to restore lost vision due to these 
diseases4 and most of the current clinical treatments are 
focused on slowing down the progression of the disease5. 
Even with highly-invasive surgical procedures such as 
retinal implants and transplants6, and stem cell therapy7, 
true restoration of vision is far from the horizon due to 
several challenges. For example, the subretinal implants8-
9
 suffers from the disadvantages of damage to the device 
over a period of time, and the microphotodiode may not 
be able to produce sufficient current to stimulate adjacent 
neurons with the use of ambient light. Similarly, the 
epiretinal implants9-10 lead to cellular proliferation due to 
surgical implantation of the device causing disordered 
stimulation patterns resulting from  electrical stimulation 
of both axons and cell bodies of ganglion cells9. Besides 
being highly invasive in nature, all the existing methods 
for restoration of vision have low spatial resolution, and 
non-specific cellular activation5.  
Cellular specificity and mechanical non-invasiveness 
can be achieved using optogenetic stimulation with high 
temporal precision by introducing a light-activated 
molecular channel, such as channelrhodopsin-2 (ChR2), 
into specific groups of cells by genetic targeting11-15. 
Since very low intensity (~mW/ mm2) light is necessary 
for optogenetic stimulation11-12, high-resolution activation 
of the degenerated retina is feasible using light from 
external µLED arrays projected to various retinal 
neuronal layers after photo-sensitization using ChR2. The 
primary method for delivery of ChR2-encoding genes to 
specific neuronal layers employs viral transfection which 
has high transduction efficiency and persistent gene 
expression16. Both non-specific transfection of the retina 
as well as promoter-specific targeting of retinal ganglion 
cells of adult mice and rats using viral methods have been 
successful17-24. However, use of viruses can lead to 
unexpected inflammatory responses, immunological 
reactions, and improper gene integration25. Further, the 
viral method limits the size of plasmid that can be 
packaged and delivered. Unlike adenoviral vectors, which 
are unable to substantially reinduce transgene expression 
by reinjection in rodents, electroporation has the ability to 
do so26, providing an important clinical advantage over 
adenoviral vectors27-28. To avoid the limitations and 
existing concerns regarding use of viruses, and because 
the eye is accessible to external delivery methods, we 
attempted in-vivo electroporation of adult degenerated 
retina of mice models and monitored expression of ChR2 
Stimulation of retinal neurons using optogenetics via use of chanelrhodopsin-2 (ChR2) has opened up a new direction 
for restoration of vision for treatment of retinitis pigmentosa (RP). Here, we report non-viral in-vivo electroporation 
of degenerated retina of adult RP-mice with ChR2-plasmids and subsequent in-vivo imaging of retina to confirm 
expression. Further, we demonstrate that in addition to efficient non-viral delivery of ChR2 to a specific retinal layer, 
threshold level of stimulation light needs to be delivered onto the retina for achieving successful behavioral 
outcome. Measurement of intensity of light reaching the retina of RP-mouse models along with geometrical optics 
simulation of light propagation in the eye is reported in order to determine the stimulating source position for 
optimal light delivery to the retina. The light-guided navigation of mice with ChR2 expressing retinal ganglion cells 
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genes in the retina, using in-vivo confocal microscopy. In 
the past, subretinal injection of plasmid DNA combined 
with electroporation resulted in efficient transgene 
expression. Further, in the case of ChR2-based treatment 
of retinitis pigmentosa, it would be highly desirable to 
reinduce transgene expression by reinjection, and 
electroporation provides this opportunity.  
While optogenetic stimulation of ON-bipolar cells20, 24 
has led to improvement of visual function, recent studies 
on stimulation of retinal ganglion cells provided 
contradictory behavioral results17, 19, 21-23. The disparity 
between the behavioral results could arise due to 
differences in expression level and/or differences in light 
intensity reaching the retina. For a successful behavioral 
outcome, it is imperative to ensure that the threshold level 
of stimulation light is delivered onto the retina to activate 
ChR2-sensitized neurons. Here, we report measurements 
of intensity of light reaching the retina of RP-mouse 
models along with geometrical optics simulation of light 
propagation in the eye, in order to determine the 
stimulating source position for optimal light delivery to 
the retina. In-vivo imaging of degenerated-retina, 
sensitized by in-vivo electroporation of adult RP mice, 
confirmed efficient ChR2 expression. The light-guided 
navigation of mice with Thy1-ChR2-YFP expressing 
retinal ganglion cells was found to be significantly 
improved over a long distance and correlated well with 
stimulation intensity.  
 
Non-viral transduction and in-vivo monitoring of 
ChR2-expression 
As an alternative to viral-based gene transfer, nonviral 
vectors are easier to prepare and less prone to cause an 
immunologic reaction. Electroporation29-31 has earlier 
been evaluated for gene delivery to the retina of adult (8 
weeks old) rd1/rd1 mice. The electroporation method can 
most easily be applied to readily accessible tissues such 
as the eye. This also removes the technical limitations on 
size of the construct (that can be inserted into the virus in 
the case of viral delivery) and therefore promoters of any 
size can be in inserted into the construct. For transfection 
by electroporation, only ChR2-plasmids were injected, 
following which the eye was placed within a hemisphere 
cathode on the cornea and a hemisphere anode with a 
groove that slides around the optic nerve on the posterior 
surface of the eye.  
Fig. 1a shows the schematic method for 
electroporation-based delivery of ChR2. The actual 
electrode for in-vivo transfection of the retina is shown in 
Fig. 1b. A function generator was used to deliver a 
variable number of pulses (width: 10 or 50 ms) separated 
by 100 ms with the voltage set at 10 or 5 V. Lipofection 
was also carried out to compare the efficiency with that 
of electroporation. For lipofection experiments, ChR2-
plasmids (promoter-ChR2-pEYFP) were suspended in 
OMEM (Invitrogen) containing 400 µl/ml of 
Lipofectamine-2000 (Invitrogen). 1 µl of vehicle mixture 
was injected using a sharpened tip of a sterilized micro-
syringe inserted through the sclera into the vitreous 
cavity. 
 
Figure 1: (a) Schematic method for electroporation-based delivery of 
ChR2. The dotted arrows show the direction of movement of plasmids 
via electroporation. (b) Actual electrode for in-vivo transfection of 
ChR2 encoding plasmids into the retina by electroporation. In-vivo 
confocal image of rd1/rd1 mice before (c) and after (d, e) expression 
of ChR2; The panels d & e show the Z-stack images of the same eye 
separated by 30 microns along the axial direction. (f) Comparison of 
efficiency of transfection by liposome and electric field mediated 
delivery; High magnification epifluorescence imaging of transfected 
(g) retinal ganglion cell and (h) axons in an explant; (i) XY and (j) 
XZ-confocal sectioning of the retina explant, immuno-stained for YFP 
and nucleus co-stained with DAPI. 
 
In order to quantify the efficiency of the in-vivo 
electroporation method, as compared to liposome 
mediated delivery, we monitored the ChR2-expression 
(Fig. 1c-e), one week after electroporation, by upright 
confocal microscopy (LSM 510, Zeiss) with a 20X long-
working distance objective. Number of cells/mm2 x 
fluorescence intensity was used as parameter for 
estimation of efficiency. Confocal imaging was carried 
out in-vivo to confirm expression before the treated mice 
were tested for light-activated restoration of vision. Seven 
days after injection of Thy1-ChR2-YFP in 1 µl of 
aqueous medium (OMEM), there was no identifiable 
gene (YFP) expression (data not shown). While use of 
only lipofectamine led to very low level expression, use 
of lipofectamine with an electric field did not lead to 
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electric field is applied on naked plasmids. In contrast, in 
all the eyes (n=6) evaluated 7 days after injection of the 
same amount of plasmid combined with electroporation 
with a power of 5 V/mm (10 pulses of 50 ms each 
separated by 100ms), the marker YFP expression was 
significant (Fig. 1d, e). For in-vivo imaging, the pupil was 
dilated using tropicamide. The panels d & e of Fig. 1 
show the Z-stack images of the same eye separated by 30 
µm along the axial direction. The pupil is marked by the 
dotted curve.  
Our results demonstrate that RGC in the central as 
well as the peripheral part of the retina is transfected. Fig. 
1f shows the comparison of efficiency of transfection by 
liposome and electric-field-mediated delivery. The high 
magnification in-vitro epifluorescence imaging of 
transfected retinal ganglion cells (Fig. 1g) shows efficient 
expression of ChR2 in both soma and axons. The 
fluorescent axonal projections can be seen in Fig. 1h. In 
order to confirm ChR2-YFP expression, immunostaining 
specific to YFP was carried out. Fig. 1(i) and (j) shows 
the XY and XZ-confocal sections of the transfected retina 
explant, immuno-stained for YFP, with nuclei co-stained 
with DAPI. As shown in Fig. 1j, the retinal ganglion cells 
in the specific layer (Thy1 promoter) are found to express 
ChR2. Thus, retinal cell-specific gene transfer is 
achievable with no lipid carrier and low-power 
electroporation.  
 
Simulation and measurement of intensity reaching the 
retina at varying distances of excitation source  
For simulating the light intensity reaching the retina, 
an in-vitro model of a mouse eye is considered,  which is 
being illuminated by a diverging blue light emerging 
from an optical fiber (core diameter: 200µm) tip placed at 
varying distances from the cornea-lens surface. Zemax 
modeling of the eye was done in the sequential mode. 
Fig. 2a shows the total power output at the retina of the 
mouse eye being irradiated at varying distances using a 
diverging optical fiber source. The peak irradiance 
reaching the retina as a function of source distance is 
shown in Fig. 2b. Fig. 2c shows the setup for 
measurement of light transmitted to the retina. The 
normalized power measured at varying distances from the 
source fiber is shown in Fig. 2d. As shown in Fig. 2d, the 
intensity of light reaching the retina is higher in the 
presence of focusing optics (cornea and lens) of the eye 
than in absence of it between the source and receiving 
fiber.  
As shown in Fig. 2a, though the total power reaching 
the retina decreases at larger distance of the source fiber, 
the peak irradiance increases (Fig. 2b).  This can be 
attributed to the fact that though some light is lost at a 
larger source distance due to the finite size of the 
collecting eye-optics and the pupil size. The imaging spot 
size decreases significantly when the source distance is 
increased from 2mm to 5mm. These two effects 
counteract leading to the obtained peak irradiance pattern 
(Fig. 2b). While peak irradiance is important for 
generating an action potential, the spot size at the retina 
will determine spatial resolution. However, the total 
transmitted-power irradiating individual cells of retina is 
important for overall stimulation efficiency. Therefore, 
for the design of a retinal prosthesis or even in evaluating 
behavioral improvements in experimental settings, these 
parameters need to be optimized in order to find the 
desired effect while using optogenetic stimulation. 
 
 
Figure 2: (a) Simulation of total power output at retina. (b) Peak 
irradiance reaching the retina, of mouse eye being irradiated at varying 
distances using a diverging optical fiber source. (c) Setup for 
measurement of light transmitted to retina, (d) Normalized power 
measured at varying distances from the source fiber. Symbol (-■-) 
denotes measurements without placing an eye in between the source 
and receiver fiber, symbol (-●-) denotes the condition where eye is 
placed in between the two fibers. 
 
In order to estimate the actual power reaching the 
retina, power measurements were carried out in the dark-
adapted mice eye, illuminated with diverging light from 
an optical fiber (200 µm core) and power measured from 
the receiving fiber (200µm core) inserted through the 
back of the eye up to retina via a guiding needle. Fig. 2d 
shows normalized power measured at the receiver fiber 
end with varying distances from the source fiber. The 
presence of the eye in between the source and the 
receiver fiber led to less decrease in received power as a 
function of source-distance (Fig. 2d). This can be 
attributed to the fact that eye-optics acting as a condenser 
in collecting the diverging light from the source and 
focusing back on to the receiving fiber. It can be noted 
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the source fiber is moved from 2 to 5 mm, while the 
theoretical simulations (Fig. 2a) based on physical optics 
propagation shows a decrease of ~7.5 times for a similar 
source-receiver distance. This discrepancy can be 
attributed to the fact that the peak irradiance increased 
(Fig. 2b) with increasing source distance. And since the 
receiving fiber has finite core size and acceptance angle, 
it cannot receive the total power reaching retina and 
therefore may not exactly match the theoretical 
simulations (Fig. 2a).  
 
Effect of improved light sensitivity of the retina on 
mouse behavior in water maze  
To determine restoration of vision, behavioral testing in a 
water maze task32 was carried out. It involved 
determination of the score for the mice swimming 
towards a stimulating light source before and after 
electro-optogenetic treatment. To determine restoration of 
vision in ChR2-transfected mice, one week after injection 
of plasmids, mice were tested with an open water maze. 
Every time the mouse was put close to the center of the 
maze, the platform was changed from the end of one arm 
to another. After training for one week, the performance 
of the mouse was recorded.  
Fig. 3a shows time-lapse sequence of a mouse 
(transfected with ChR2) moving towards the light source. 
The platform inside the water maze, acts as a reward 
system to mice that are constantly swimming since they 
can rest instead of having to swim. The mice with 
restored vision (eye treated by electroporation of Thy1-
ChR2-YFP) were able to respond to the light emitted 
from the LED array and were able to reach the platform 
faster than untreated. Since the LED light is diverging, 
the intensity of light decreases away from the source (Fig. 
3b). The behavioral improvement of the treated mice was 
found to depend on the intensity of the activation light 
with a threshold intensity (or distance) from where the 
treated mouse could respond to the light (Fig. 3c). Since 
the mice are swimming in the water maze, the platform 
provides a reward to them where they can rest instead of 
having to swim.  
Before electroporation, the rd1/rd1 mice are 
considered as controls. The mice with restored vision 
(eye treated by electroporation of Thy1-ChR2-YFP) were 
able to respond to the light emitted from the LEDs and 
were able to reach the platform faster than untreated 
mice. The behavior of the treated mice was found to 
depend on the intensity of the activation light with a 
threshold intensity (or distance) from where the treated 
mouse could respond to the light. Since the LED light is 
diverging, the intensity of light decreases away from the 
LED source. The mouse was placed at various distances 
along the beam path in order to find out the threshold 
light intensity. The variation of stimulation intensity at 
different distances from the source (Fig. 3b) correlates 
well with the mouse swimming score (Fig. 3c). The score 
is defined as the percent of mice reaching the platform 
based on their initial position (when the light was 
switched on). 
 
Figure 3: (a) Time-lapse sequence of mouse (transfected with ChR2) 
moving towards light source, (b) Intensity of light from the LED array 
as a function of distance from the source, (c) % of mice reaching the 
platform as a function of distance from light source.  
 
Both non-specific transfection of the retina as well as 
promoter-specific targeting of bipolar and retinal 
ganglion cells of adult mice and rats using viral methods 
have been established17-24. Though it has been recently 
reported that ChR2-protein is non-toxic and do not lead 
to an immune response24, significant concerns such as the 
immune response exist for current viral delivery 
methods25,33. Further, for a viable ChR2-based human 
therapy, the expression of ChR2 must be stable, robust, 
and reinducible. When adenoviral vectors are injected 
into the eye to transduce retinal cells, the transgene 
expression peaks within a few days and then declines and 
is generally undetectable by one month after injection 34. 
Unlike adenoviral vectors, which are unable to 
substantially reinduce transgene expression by reinjection 
in rodents34, electroporation has been able to do so26, 
providing an important advantage over adenoviral 
vectors. In spite of our current results which show that 
ChR2-protein expression is stable and remains functional 
for several months, in the case of ChR2 based treatment, 
it would be highly desirable to reinduce transgene 
expression by reinjection, and electroporation provides 
this opportunity. Low power electroporation without any 
lipid carrier provided efficient retinal cell-specific gene 
transfer using optimal electric field parameters (strength, 
pulse duration, and number of pulses). While in vivo 
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the whole retina, it will be highly desirable to 
optogenetically treat only those areas of the retina that 
have undergone photodegeneration rather than the whole 
retina. To achieve this scanning near the IR laser 
microbeam can be used for delivery of ChR2 to localized 
areas of the retina35. Such uniqueness in spatially-targeted 
delivery of genes to the peripheral retina will be ideal for 
restoring lost-vision of RP patients experiencing tunnel 
vision during aging.  
Recent use of light sensitive chloride channel 
(Halorhodopsin) expression in longer-persisting cone 
photoreceptors has shown new promise for therapeutic 
intervention for restoration of vision36. Since the 
proposed electro/optoporation method will not only 
eliminate the requirement of viral delivery, it will be able 
to deliver light-sensitive ion-channels (ChR2 and 
Halorhodopsin) to spatially targeted degenerated retina 
areas, thus paving the way for translation of the 
technology to clinical trials. Our success in guiding the 
optogenetically treated rd1/rd1 mouse over a distance of 
100cm was attributed to efficient transfection of retinal 
ganglion cells, optimal light (intensity) delivery and 
careful training.  
 
Conclusions 
Stimulation of retinal neuronal cells using optogenetics 
via use of chanelrhodopsin-2 and blue light has opened 
up a new direction for restoration of vision with respect 
to the treatment of retinitis pigmentosa. In contrast to 
earlier viral-method-based delivery of ChR2 onto retinal 
ganglion cells, we successfully demonstrated in-vivo 
electroporation of the RP mice eye and improved 
behavior subsequent to ChR2 transfection. Our 
simulations and measurement of intensity distribution of 
light reaching the retina of the RP mouse models showed 
that optimal divergence and distance of the stimulating 
source is required for efficient delivery of light to the 
retina. Further, the spot size at the retina, contributing to 
the spatial resolution in optogenetically restored vision, 
was found to depend on the source positioning. The 
behavioral improvement in mice with ChR2 transfected 
retina was found to correlate with the stimulation 
intensity reaching the retina.  
 
Materials and methods 
Mouse preparation 
Retinal degenerated mice (rd1/rd1 - C57BL/6J-Pde6brd1-
2J) and C57BL/6 wild type mice (control) were obtained 
from Jackson laboratory and bred in the animal facilities 
of the university. Mice were maintained on a 12:12 light 
cycle (lights on at 07:00). Once the animals were 
acclimated to the animal facility for ~1 week, they were 
anesthetized with 90 mg/kg ketamine, 10 mg/kg xylazine 
and placed in a stereotaxic frame (Kopf Instruments). In 
all experiments attention was paid to the ethical 
guidelines for investigations of experimental pain in 
conscious animals, and the procedures were approved by 
the IACUC. 
 
Transfection of ChR2-YFP into rd1/rd1 mouse retina 
Adult (8 weeks old) rd1/rd1 mice were treated 
humanely in strict compliance with IACUC on the use 
of animals in research. For transfection of specific 
layers of retina in-vivo electroporation and lipofection 
was used. ChR2-plasmids with Thy1 promoter to target 
retinal ganglion cells, and pEYFP was fused for 
visualization of expression. For lipofection 
experiments, ChR2-plasmids (promoter-ChR2-pEYFP) 
were suspended in OMEM containing 400 µl/ml of 
Lipofectamine-2000 (Invitrogen). Mixtures of plasmids 
and lipid-containing media were incubated for 20 
minutes at room temperature before injection. Before 
intra-vitreous injections, mice were anesthetized, 
pupils were dilated, and a sharpened tip of a sterilized 
micro-syringe was inserted through the sclera into the 
vitreous cavity. For electroporation, the injections were 
carried out with a 32-G needle on a Hamilton micro-
syringe to deliver 1 µl of plasmids into each eye, 
following which the eye was placed within a 
hemispherical cathode on the cornea and a 
hemispherical anode with a groove that slides around 
the optic nerve on the posterior surface of the eye. A 
function generator was used to deliver a variable 
number of pulses (width: 10 or 50 ms) separated by 
100 ms with the voltage set at 10 or 5 V. 
  
Behavioral assessment 
The mice were divided into 3 groups. Mice in group 1 
(control) were trained in the water maze task for a 
duration of 7 days and then tracked twice a week for 
about 4 weeks. Mice in group 2 were injected with 
ChR2 construct (Thy1-ChR2-pEYFP), followed by 
electroporation. Mice in group 2 were trained in the 
water maze task for a period of 7 days prior to 
transfection. A removable platform with a diameter of 
6 cm and height of 8 cm was placed into the pool. The 
maze was then filled with water to a depth of 7 cm at a 
temperature of 25°C. A diverging LED array (Rep rate: 
10Hz) was directed into center of the maze. The light 
intensity at different distances was measured with a 
power meter (PM100D, Thorlabs Inc.). One week after 
injection of plasmids, mice behavior in water maze 
task was quantified twice a week at varying distances 
from the light source. Ethovision software was used to 
analyze the behavior of mice in the maze. % of mice 
finding the platform (light source) was scored to 
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External light source parameters 
For the light intensity at the retina to be above the ChR2 
stimulation threshold, the light source should have 
sufficient brightness and optimal divergence so that 
maximum light can be collected and focused by the 
cornea-lens on to the retina. Unlike highly-packed 
pigments in photoreceptors of intact retina which 
amplifies the signal in cascade, cells expressing ChR2 
only on the membrane would require orders of magnitude 
higher light intensity to elicit action potentials. The 
required photon flux to achieve this depends on the level 
of ChR2 expression. Assuming maximum ChR2 
expression (2x107 for a cell of diameter 10µm and ChR2 
ion channel cross-section ~10nm2), Grossman et al.20 
have calculated the lower and upper bound for the 
generating action potential to be ~ 0.05 mW/mm2 and 
10mW/mm2, respectively, for blue light (470 nm). From 
this threshold, cell irradiance, required for generating the 
action potential and the transmission characteristics of the 
eye; one can estimate the required radiance of the 
external light source. The source size, its position from 
the cornea and divergence need to be optimized for 
getting optimal modulation transfer function of the 
imaging system (eye).  
 
Immunostaining  
After extraction of the retina, it was incubated for 30 min 
in 0.25% Triton X-100 and 1% bovine serum albumin 
(BSA) for 10 minutes. The retina explant was then 
washed and mounted on gelatin-coated slides, treated 
with fluorescent-mounting media, and coverslipped. 
Primary antibody incubation was performed 1 hr at room 
temperature in 1% BSA/PBS (goat anti-YFP 1:200, 
Abgent). Sections were then washed and incubated with 
secondary antibody (Rabbit anti-goat, FITC 1:500, 
Invitrogen) for 1 hr at room temperature. Following 10 
min incubation with Hoechst (1µg/mL), sections were 
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